

18 Dec 2018

Oral typhoid vaccine updated Summary of Product Characteristics (SPC)

Vivotif® SPC updated to provide three years protection and minimum age for vaccination reduced to five years

The Summary of Product Characteristics (SPC) for oral typhoid vaccine, Vivotif® has been updated [1]. In line with Public Health England's 'Green Book' Immunisation against infectious disease, the Vivotif® SPC now indicates revaccination at three years for travellers at continued risk [1,2]. Previously Vivotif's licence covered one year of protection for travellers.

The updated Vivotif® SPC now indicates vaccination for adults and children aged five years and older [1]. Previously the marketing authority (licence) covered use in children from six years of age. Guidance on the use of Vivotif® in those aged five years is awaited from the [Joint Committee on Vaccination and Immunisation](#).

Vivotif® vaccination is taken orally; the dose is one capsule taken on alternate days (three capsules in total). Each capsule should be taken with cold or lukewarm water (temperature not more than 37°C) on an empty stomach and at least one hour before the next meal [1]. Note that the vaccine capsule should not be chewed and should be swallowed whole as soon as possible after placing in the mouth [1]. This may be difficult for some young children.

Health professionals should ensure they are familiar with the Summary of Product Characteristics before prescribing the vaccine.

Resources

- [PaxVax Vivotif Summary of Product Characteristics](#)

References

1. [PaxVax Vivotif Summary of Product Characteristics, 7 December 2018 \[Accessed 18 December 2018\]](#)
2. [Public Health England, Typhoid, in Immunisation against infectious disease, 28 August 2015 \[Accessed 18 December 2018\]](#)